Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$1.29
-$0.01(-0.78%)
At close: 4:00 PM EDT
$1.29
-$0.01(-0.78%)
Day’s Range― - ―
52-Week Range$1.25 - $17.63
Previous CloseN/A
Volume62.46K
Average Volume (3M)781.31K
Market Cap
$5.86M
Enterprise Value-$2.79
Total Cash (Recent Filing)$8.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.46
Shares Outstanding4,475,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Minimal Debt And Improved EquityMinimal debt limits interest obligations and financial leverage, while improved equity provides a stronger capitalization base than in 2025. This gives Enveric greater flexibility to fund development, although it does not eliminate future financing needs.
Losses Have Improved From Prior YearsThe reduction in losses from earlier periods suggests some expense discipline as the company advances its pipeline. Sustained cost control could extend its development runway, though the business remains far from breakeven and has no commercial revenue.
Focused Neuroplastogenic Drug Development ModelA focused small-molecule platform targeting depression and anxiety gives Enveric a defined therapeutic strategy and potential differentiation from classic psychedelics. Long-term value depends on clinical validation, regulatory progress, and eventual commercialization.
Bears Say
Pre-Revenue And Persistently UnprofitableWithout revenue, Enveric lacks internally generated funding for research and development, while recurring losses indicate that commercial economics remain unproven. The company must achieve successful development and launch milestones before this fundamental weakness can materially improve.
Continued Cash Burn Requires External FundingPersistent operating and free cash outflows reduce financial runway and leave the company dependent on financing or a major partnership milestone. Until revenue emerges, continued cash consumption can constrain pipeline investment and increase shareholder funding risk.
Ongoing Equity Issuance Creates Dilution RiskRepeated reliance on an at-the-market equity program provides capital to support operations but increases the share count and can dilute existing holders. This financing dependence is likely to remain relevant while the company has no revenue and continues burning cash.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.25 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $5.86M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.759 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$0.759 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.583%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
13.67% Insiders
0.18% Mutual Funds
8.03% Other Institutional Investors
76.87% Public Companies and
Individual Investors